California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in near-term payments for rights to a T-cell engager (TCE) for autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results